[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537939":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":24,"centralContacts":32,"locations":39,"responsibleParty":56,"collaborators":59,"id":62,"slug":10,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":84,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients affected by Gynecologic Cancer undergoing systemic antineoplastic treatment",null,"Study population will consist of subsequent patients prospectively enrolled at the time of prescription of a new line of systemic antineoplastic treatment for a gynecologic oncological disease, defined as ovarian, tubal, uterine, cervical, vaginal, or vulvar neoplasm",[13],"Drug: Anticoagulant",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Anticoagulant","Prescription of pharmacological thromboprophylaxis according to current clinical practice and international guidelines recommendation",[9],[21,22,23],"Low Molecular Weight Heparin","Apixaban","Rivaroxaban",[25,29],{"name":26,"affiliation":27,"role":28},"Roberto Pola, PhD; MD","Agostino Gemelli University Polyclinic Foundation IRCCS","PRINCIPAL_INVESTIGATOR",{"name":30,"affiliation":27,"role":31},"Paolo Santini, MD","STUDY_CHAIR",[33,37],{"name":26,"role":34,"phone":35,"phoneExt":10,"email":36},"CONTACT","+39 0630157075","roberto.pola@policlinicogemelli.it",{"name":30,"role":34,"phone":10,"phoneExt":10,"email":38},"paolo.santini@guest.policlinicogemelli.it",[40],{"facility":27,"status":41,"city":42,"state":10,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Rome","00168","Italy",{"type":46,"coordinates":47},"Point",[48,49],12.51133,41.89193,{"lat":49,"lon":48},[52,53,54],{"name":26,"role":34,"phone":35,"phoneExt":10,"email":36},{"name":30,"role":34,"phone":10,"phoneExt":10,"email":38},{"name":30,"role":55,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"type":28,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Pola Roberto","Professor",[60],{"name":61,"class":6},"Fondazione Umberto Veronesi","100537939",false,"NCT06284343","The Gynecological Cancer Associated Thrombosis (GynCAT) Study","Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study","GynCAT","Inclusion Criteria:\n\n* Female sex;\n* Diagnosis of gynecologic neoplasm (ovarian, tubal, uterine, cervical, vaginal, vulvar neoplasm);\n* Planned new line of systemic antineoplastic treatment;\n* Age of 18 years or older;\n* Accordance of Informed Consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women;\n* Indication to receive therapeutic dose anticoagulant therapy (e.g., atrial fibrillation, mechanical heart valve);\n* Diagnosis of symptomatic VTE at the time of screening for enrollment.","FEMALE","18 Years",{"count":72,"type":73},1800,"ESTIMATED","OBSERVATIONAL","GynCAT is a prospective cohort study that will be conducted on female patients with gynecologic malignancies scheduled for systemic antineoplastic treatment, aiming at development and validation of a Risk Assessment Model (RAM) for Venous Thromboembolism (VTE) in this specific population.",[77,78,79,80,81,82,83],"Cancer-associated Thrombosis","Venous Thromboembolism","Gynecologic Cancer","Ovarian Cancer","Cervix Cancer","Endometrial Cancer","Vaginal Cancer",[85,86,87,80,83,82,79],"Thrombosis","Venous thromboembolism","Cancer","2024-09-17",{"date":90,"type":91},"2024-09-19","ACTUAL",{"date":93,"type":91},"2024-04-15",{"date":95,"type":73},"2026-09-30",{"name":5,"class":6},1]